360 Stem Cell & Regenerative Medicine Newsletter- November 13, 2015

 weSRCH's Best of the Internet Award
  16th-Nov-2015
 232

360 Stem Cell & Regenerative Medicine Newsletter - Nov 13, 2015

Featured video:

UGA’s “Jurassic” Experiments to Save Endangered Species
“Scientists at the University of Georgia are channeling Jurassic Park to save endangered species. Their goal is to develop a tiger embryo from skin and stem cells and artificially inseminate a house cat to save endangered cats from extinction.” 360 Editor’s comment: What are the human implications? We live in the era of “Future Shock” with technologies converging and advancing at a pace challenging human comprehension. Learn more about this “Jurassic Project” on the panel “Evolution and De-Extinction: The Frozen Zoo and Cloning the Mammoth” at the upcoming World Stem Cell Summit, Hyatt Regency Atlanta- Dec. 10-12 .

World Stem Cell Summit

The New York Times: Astellas Pharma to Acquire Ocata Therapeutics
“Ocata Therapeutics, a sometimes controversial pioneer in developing human embryonicstem cells, will be acquired by Astellas Pharma for about $379 million. Astellas, one of the major drug companies in Japan, will make a tender offer worth $8.50 a share in cash, a 79 percent premium to Ocata’s closing price on Friday. Ocata’s shares rose 89 percent to $8.44 on Tuesday. Shareholders must still approve the deal by tendering their shares. Despite its small size, Ocata, known for most of its existence as Advanced Cell Technology, has often been in the headlines for pushing the frontiers of cloning and embryonic stem celltechnology. It is arguably the most advanced company in testing medical treatments derived from human embryonic stem cells. Such cells are controversial because their creation usually involves the destruction of human embryos (though Ocata says it can avoid embryo destruction).” 360 editor’s comment: The Ocata f/k/a Advanced Cell Technology odyssey is a science and business saga worth remembering- embracing stem cell entrepreneur and visionary Dr. Mike West, brilliant scientist Dr. Bob Lanza and a host of tenacious business managers that somehow kept the dream alive while the company survived on fumes. Somewhere in the cosmos, Bill Caldwell is smiling. There are geo-political implications to this transaction, as extremely valuable IP relating to pluripotency moves to a Japanese company. Japan is leading the way to a stem cell future with companies like Astellas and FujiFilm making large investments in U.S. companies.

Xconomy: With $379M Deal For Ocata, Astellas Buys Stem Cells For Eye Diseases
Here is some additional coverage. Journalist Alex Lash wrote this analysis published in Xconomy.

Update: World Stem Cell Summit & RegMed Capital Conference- Atlanta- Dec. 10-12

Less than a month! Hotel room block nearly sold out. Register today.

The nonprofit, public interest organizations, Genetics Policy Institute and Regenerative Medicine Foundation have merged our operations and projects. One result is that our three annual meetings are now combined - the World Stem Cell Summit (11th year), RegMedCon (4th year) and RegMed Capital Conference (2nd year). The result is the 2015 World Stem Cell Summit & RegMed Capital Conference - a mission driven event- providing a window to the world for stem cell and regenerative medicine, in all its aspects. The three-day, 7-track event showcases 90 sessions (!), including panels, keynotes, symposia and workshops in the areas of Discovery- Translation & Clinical Trials- Regenerative Services & Applications (the “here and now”)- Ethics, Law & Society (ELSI)- Innovation Showcase: Cell Manufacturing, Regenerative Engineering and Bio-Processing- Hot Topics & Future Trends- RegMed Capital Conference. The capital conference includes 24+ company presentations to investors. The Summit program boasts more than 225 experts and leaders, 1,200+ total attendees from 40 countries.

See speakers. See agenda. See sponsors.

Elplasia

CTV National News: Canadian Researchers Break Blood-Brain Barrier with New Ultrasound Treatment
“Canadian scientists have made history with a world first, successfully using focused ultrasound to break through one of the human body's final frontiers -- the blood-brain barrier. The researchers have unlocked a non-invasive way to deliver medication deep into the brain, opening the door to better treatments for brain tumors, Alzheimer's, Parkinson's and more.”

Medical Express: Researchers Aim to Regenerate Human Knees and Limbs by 2030
“On Veteran's Day (U.S.) the University of Connecticut announced the launch of its new grand research challenge: regeneration of a human knee within 7 years, and an entire limb within 15 years. This major international research undertaking, called The HEAL Project, stands for Hartford Engineering a Limb. It is the brainchild of UConn Health's Cato T. Laurencin, a leading surgeon-scientist in orthopaedic surgery, engineering, and the new field of regenerative engineering. His laboratory research successes include the growth of bone and knee ligaments.”

Stembiosys

University of Toronto: Stem Cell Exhibit for Kids is a Hit with Adults Too-
Teaching School Kids “Mere Steps from the Place Where Stem Cells Were Discovered”

“An award-winning stem cell exhibit has been delighting children, parents/grandparents and educators since it arrived at MaRS Discovery District, and Torontonians have a few more days to view it before it moves on to its next location. Super Cells: The Power of Stem Cells is a free, interactive, museum-quality exhibit that introduces children between the ages of four to 14 years old to the wonders of stem cells. Brought to Toronto by the Centre for Commercialization of Regenerative Medicine (CCRM), with funding provided by the University of Toronto to support science public outreach, the tri-lingual exhibit (English, French and Spanish) has quickly become integrated into science curriculums for the schools that have visited.”

Ajinomoto

Mayo Clinic Awarded $5.3 Million Federal Grant to Study Vascular Risk Factors in Dementia
“Mayo Clinic’s Florida campus was awarded a $5.3 million grant from the National Institutes of Health (NIH) to identify vascular risk factors in aging and dementia, and translate that knowledge into studying potential targets for treatment. The grant is one of the first awarded as part of the National Alzheimer’s Project Act, which called for an aggressive and coordinated national Alzheimer’s disease plan. The first goal of the national plan is to prevent and effectively treat Alzheimer’s disease by 2025. The NIH grant will fund a five-year study of the association between vascular disease and Alzheimer’s and related dementias, pulling together Mayo’s teams in Florida and Minnesota working on laboratory studies, population studies, patient-provided data, and brain pathology.”

RegMedNet

The Ripon Advance: Bi-Partisan (U.S.) Blood Banking Act Would Help Families Preserve Stem-Cell-Rich Blood, Tissue
“U.S. Reps. Erik Paulsen (R-MN) and Ron Kind (D-WI) introduced the Family Cord Blood Banking Act, which aims to help families who want to preserve umbilical cord and placental blood and tissue, which contain stem cells that can be used later to treat the child and close relatives for blood disorders. The bill would make the collection and storage of cord and placental blood and tissue a qualified expense for Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs).”

360 Newsletter Editor

Bernard Siegel
Executive Director
Genetics Policy Institute




2015 World Stem Cell Summit

About GPI

The nonprofit Genetics Policy Institute (GPI) seeks to establish a positive policy, regulatory and societal framework to enable research to flourish, under the highest ethical and medical standards. We seek to accelerate the discovery and development of lifesaving cures and therapies to alleviate human suffering due to chronic and terminal afflictions. Visit Website.

ConnectGPI on FacebookGPI on TwitterGPI on LinkedIn


Genetics Policy Institute (GPI) and the Regenerative Medicine Foundation (RMF) Announce Merger Plan

Domain: Medical
Category: Biology

Recent Newsletters

12 March, 2019
10 October, 2018
15 February, 2018